WO2024201385 - COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND KILLER CELLS

National phase entry:
Publication Number WO/2024/201385
Publication Date 03.10.2024
International Application No. PCT/IB2024/053054
International Filing Date 28.03.2024
Title **
[English] COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS AND KILLER CELLS
[French] COMPOSITIONS, SYSTÈMES ET MÉTHODES DE TRAITEMENT DU CANCER À L'AIDE DE CHAMPS DE TRAITEMENT DE TUMEURS ET DE CELLULES TUEUSES
Applicants **
NOVOCURE GMBH
Inventors
KAN, Tal
BARSHESHET, Yiftah
Priority Data
63/493,141   30.03.2023   US
63/599,142   15.11.2023   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting2308
EPO Filing, Examination, Granting10951
Japan Filing, Examination, Granting2309
South Korea Filing, Examination, Granting2418
USA Filing, Examination, Granting4740
MasterCard Visa
Total: 22,726

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] Compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field concurrently with administration of at least one composition comprising at least one killer cell (such as, but not limited to, at least one natural killer (NK) cell or at least one cytokine‐induced killer (CIK) cell).[French] La divulgation concerne des compositions, des systèmes et des méthodes pour réduire la viabilité de cellules cancéreuses et traiter le cancer, ainsi que pour prévenir une augmentation du volume d'une tumeur présente dans le corps d'un patient vivant. Les systèmes et les méthodes impliquent l'application d'un champ alternatif simultanément avec l'administration d'au moins une composition comprenant au moins une cellule tueuse (telle que, mais sans y être limitée, au moins une cellule tueuse naturelle (NK) ou au moins une cellule tueuse induite par cytokine (CIK)).